Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck

Kim, Gwi Eon; Lee, Sang Wook; Chang, Soo-Ho; Park, Hee Chul; Pyo, Hong Ryull; Kim, Joo Hang; Moon, Sun Rock; Lee, Hyeong Sik; Choi, Eun Chang; Kim, Kwang Moon

doi:10.1016/s0167-8140(01)00428-5

Cited by 80 publications

(45 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among non-ALCL PTCL subtypes, the 5-year OS ranged between 28% and 36% in AITL, 45% in PTCL-NOS, and <25% in patients with ETTL [24, 32, 36]. For NK/T-cell NHL, 5-year OS was 25%–77% depending on the treatment modality [26, 31–33, 35, 43]. Chemotherapy plus RT resulted in the same 5-year OS as RT, and both modalities were superior to chemotherapy alone [26, 31, 33, 35, 37, 43].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

et al. 2011

View full text Add to dashboard Cite

Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its benefits have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4–50.7%) for enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0–75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year OS was 38.5% (95% CI 35.5–41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5–31.2%) for ETTL to 56.5% (95% CI 42.8–69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the benefits of anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes for these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The importance of chemotherapy for early-stage NKTCL has been previously challenged by several retrospective studies because the prognoses of patients treated with RT plus chemotherapy or RT alone were comparable [21,[25][26][27]. Similarly, RT plus CHOP or CHOP-like chemotherapy failed to demonstrate a therapeutic advantage over RT alone in elderly patients with early-stage NKTCL in Wang's study [18].…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma

Xia

Zhang

et al. 2015

Ann Hematol

View full text Add to dashboard Cite

The optimal treatment strategy for elderly patients with natural killer/T-cell lymphoma (NKTCL) remains to be established. A total of 63 elderly patients with newly diagnosed NKTCL were retrospectively reviewed. Among the patients with stage I-II disease, 58.3 % received radiotherapy (RT) ± chemotherapy, and 41.7 % received chemotherapy alone. Compared with chemotherapy alone, RT ± chemotherapy elicited a significantly higher overall response rate (ORR) (100 vs. 57.1 %, P < 0.001) and substantially prolonged 5-year overall survival (OS) (55.3 vs. 18.0 %, P < 0.001) in patients with stage I-II disease. Compared with other chemotherapeutic regimens, pegaspargase plus gemcitabine and oxaliplatin (PGEMOX)/L-asparaginase plus gemcitabine and oxaliplatin (GELOX) was associated with a significantly higher ORR (92.9 vs. 51.6 %, P = 0.009) and a significantly improved 5-year OS (78.6 vs. 23.9 %, P = 0.010) in patients with stage I-II disease. Nine patients with stage I-II disease who were treated with PGEMOX/GELOX followed by RT had an encouraging outcome (5-year OS 100 %, 5-year progression-free survival (PFS) 85.7 %), which was superior to that of patients receiving other regimens followed by RT. In conclusion, RT played an important role for elderly patients with early-stage NKTCL, and the PGEMOX/GELOX regimen was superior to other regimens. The combination of them may be a promising treatment option.

show abstract

“…7) (415051). Radiotherapy has been validated as primary treatment for localized nasal NK/T-cell lymphoma in several large retrospective studies (5253545556). As expected, patients with early stage disease have a better prognosis as compared to patients with advanced disease.…”

Section: Subtypes Of T-cell Nhlsmentioning

confidence: 99%

T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes

et al. 2017

View full text Add to dashboard Cite

T-cell non-Hodgkin lymphomas (NHLs) are biologically diverse, uncommon malignancies characterized by a spectrum of imaging findings according to subtype. The purpose of this review is to describe the common subtypes of T-cell NHL, highlight important differences between cutaneous, various peripheral and precursor subtypes, and summarize imaging features and the role of imaging in the management of this diverse set of diseases.

show abstract

Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck

Cited by 80 publications

References 41 publications

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma

T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes

Contact Info

Product

Resources

About